drugset / Trial / NCT02390375

Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia

NCT02390375

Phase 3 Completed 348 enrolled Daewon Pharmaceutical Co., Ltd.
RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of the DW0929 in patients with primary hypercholesterolemia

Timeline

Start
2014-11
Primary completion
2016-04
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject DW-0929 Unknown 5 mg
Subject DW-0929 Unknown 10 mg
Subject DW-0929 Unknown 20 mg
Comparator Rosuvastatin Small molecule 5 mg
Comparator Rosuvastatin Small molecule 10 mg
Comparator Rosuvastatin Small molecule 20 mg

Indications